Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

According to the Cleveland Clinic, these drugs, known as GLP-1 inhibitors, help manage blood sugar levels by triggering insulin release from the pancreas. The drugs also help slow digestion ...

Certain diabetes medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, are associated with weight reduction, which may contribute to muscle mass loss and, consequently ...

SGLT2 inhibitors such as empagliflozin, and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce ...

Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

25). The trial is the first to test the cardiovascular benefits of an oral GLP-1 inhibitor. Both injectable and oral forms of semaglutide are already approved by the U.S. Food and Drug ...

One study found that GLP-1 drugs were associated with a 33 per cent reduction in the risk of dementia, while another class of diabetes medications, SGLT2 inhibitors, demonstrated an even greater ...